Latest Licensing Deals News

Starpharma reports strong progress in strategic collaborations and internal drug development, alongside a 70% surge in Viraleze™ online sales and a solid $18.2 million cash position.

Atomo Diagnostics reported a robust 121% quarter-on-quarter revenue increase to $1.5 million, driven by new orders for its FebriDx Pascal and HIV Self-Test products. The company also secured a global licensing deal for a novel liver function test and expanded manufacturing capacity to support growing demand.

Cambium Bio has strengthened its financial footing with a $0.6 million R&D tax refund and a $2.4 million strategic placement, setting the stage for pivotal Phase 3 clinical trials of its lead ophthalmology candidate.

Arovella Therapeutics has filed an IND application for its lead CAR-iNKT therapy ALA-101, selected a CRO for its upcoming phase 1 trial, and secured $19.4 million in cash to fund clinical progress and pipeline expansion.

Audeara Ltd reported a strong Q2 FY26 with revenues up 274% year-on-year, securing key regulatory approval in China and expanding its global licensing footprint.

Atomo Diagnostics has locked in exclusive global rights to a novel liver function test that rapidly detects liver injury, expanding its footprint in point-of-care diagnostics. The test, delivered on Atomo’s Pascal platform, targets drug-induced liver injury and chronic liver conditions with significant commercial potential.

AdAlta Limited has raised A$1.2 million through a strategic placement to advance its innovative PD1 armored MSLN CAR-T therapy for solid cancers, reinforcing its unique 'East to West' cellular immunotherapy approach.

Origin Energy backs a landmark US$1 billion equity raise for Kraken Technologies, valuing the company at US$8.65 billion and maintaining a significant stake as Kraken prepares to separate from Octopus Energy.

Weebit Nano has raised its FY26 revenue guidance to a minimum of $10 million following the signing of multiple IP licensing agreements with semiconductor fabs and product companies.

Weebit Nano has inked a long-term licensing deal with semiconductor giant Texas Instruments to integrate its advanced ReRAM technology into TI’s embedded processing chips, marking a significant step for next-generation memory solutions.

Neurizon Therapeutics has launched a A$24.2 million equity raise to fund the next phase of clinical trials for its lead drug NUZ-001 targeting ALS, supported by a global licensing deal and a flexible convertible note facility.

archTIS has renewed 1,000 NC Protect licenses within the U.S. Department of Defense’s Microsoft DoD365 environment and secured an $8 million debt facility to accelerate its U.S. market expansion.